AB Science SA, a pharmaceutical company focused on research, development and marketing of protein kinase inhibitors (PKIs), has announced that it is hosting a web conference including key opinion leaders and experts covering its experimental therapy masitinib and its utility to treat amyotrophic lateral sclerosis (ALS). The web conference call will be held from 5:35 pm to 6:35 pm on May 11, 2015.
The web conference will be an opportunity for investors and other stakeholders to gain a better understanding of several topics such as the positioning of masitinib in ALS, the science behind the development of masitinib in ALS, the safety and efficacy updates concerning the phase 3 study that is currently ongoing and the market potential of masitinib for ALS.
A Q&A session will follow and several experts in ALS will answer questions and encourage discussion. Luis Barbeito from the Institut Pasteur de Montevideo, Montevideo, Uruguay; Benjamin Brooks from the Department of Neurology, Carolinas Medical Center, Charlotte, USA; Conrado Estol from the STAT Research, Buenos Aires, Argentina; Olivier Hermine from the Division of Hematology/Oncology, Necker University Hospital, Paris, France; Jesus S. Mora from the ALS Unit, Hospital Carlos III, Madrid, Spain.
After completion of the web call, the presentation will be made available on the AB science website.
Masitinib is a novel, orally administered tyrosine kinase inhibitor that targets mast cells and macrophages by inhibiting kinases (macrophages are important cells of the immunity system). The experimental drug has a specific mechanism of action and can be developed for a large amount of conditions in oncology, in diseases of the central nervous system, and in inflammatory conditions. According to the company, Masitinib, alone or in combination, has shown evidence of having a positive effect on survival in ALS. The therapy can inhibit the inflammatory process and has positive effects concerning the degeneration related with these conditions.
Read More Recent News
A research team from Pitié–Salpêtrière Hospital in Paris found major structural alterations of the neuromuscular junctions (NMJs) in early stage Amyotrophic Lateral Sclerosis (ALS) patients. The study entitled “Endplate denervation correlates with Nogo-A muscle expression in amyotrophic lateral sclerosis patients” was published April 2015 inAnnals of Clinical and Translational Neurology.